Zynex INC

Zynex, Inc. successfully exited Chapter 11 bankruptcy, implementing a reorganization plan that included new financing, cancellation of all prior equity, and significant corporate governance changes.

Zynex, Inc. has received court confirmation for its Chapter 11 reorganization plan, which will cancel existing common stock and transfer ownership to a new Plan Sponsor.

Zynex, Inc. announced the conclusion of an SEC investigation with no enforcement action intended, amidst ongoing Chapter 11 bankruptcy proceedings and delisting from Nasdaq.

Zynex, Inc. announced its common stock delisting from Nasdaq and subsequent trading on the Pink Limited Market, alongside filing an amended Chapter 11 reorganization plan.

Zynex, Inc. removed its Chair, Thomas Sandgaard, following his federal indictment for healthcare and securities fraud, as the company navigates Chapter 11 bankruptcy and Nasdaq delisting.

Zynex, Inc. has amended its debtor-in-possession financing and filed a joint plan of reorganization as it navigates Chapter 11 bankruptcy proceedings.

Zynex, Inc. reports significant net losses and revenue declines, raising substantial doubt about its ability to continue as a going concern, while grappling with a Tricare payment suspension, multiple lawsuits, and an SEC investigation.

Zynex, Inc. disclosed significant net losses and a substantial revenue decline for the second quarter and first half of 2025, primarily due to a temporary payment suspension from Tricare and reduced device orders, while also revealing an SEC investigation and expressing substantial doubt about its ability to continue as a going concern.

Zynex, Inc. reported a significant 43% drop in net revenue and a net loss of $10.4 million for Q1 2025, primarily driven by a temporary payment suspension from TriCare and a class action lawsuit alleging securities fraud.

Zynex's Q1 2025 revenue decreased by 43% year-over-year due to a temporary payment suspension from TriCare and a decline in device orders.

Zynex's Q3 2024 results show a slight increase in revenue but a decrease in net income compared to the same period last year.

Zynex, Inc. announced an 11% increase in revenue for both the three and six months ended June 30, 2024, driven by increased device orders, though net income decreased compared to the same periods in 2023.

Zynex, Inc. filed an amended annual report detailing a temporary payment suspension from Tricare, a 10% staff reduction, and identified material weaknesses in internal controls, despite achieving revenue growth and its ninth consecutive profitable year.

Zynex reports a 4% increase in revenue for 2024 while implementing a restructuring plan to address temporary payment suspensions.

Zynex Inc. reports a 17% increase in revenue and a 29% increase in operating cash flow for 2023, alongside strategic investments in sales and product development.

Zynex Inc. Director Barry D. Michaels reports the cancellation of all common stock for no consideration following the company's Chapter 11 reorganization plan.

Zynex director Joshua Disbrow reports the cancellation of all ZYXI common stock and equity awards for no consideration following the company's Chapter 11 reorganization.

Zynex Director Michael Cress reports cancellation of all common stock and restricted stock awards for no consideration following the company's Chapter 11 reorganization plan.

Zynex Inc.'s Chief Operating Officer, Anna Lucsok, reported the grant of 7,500 restricted stock units and the withholding of shares for tax obligations.

Zynex Inc.'s Chief Financial Officer, Daniel J. Moorhead, reported the acquisition of 5,000 restricted stock units and the withholding of 3,982 shares for tax purposes, as detailed in a recent SEC Form 4 filing.

Director Joshua R. Disbrow reports a stock award and holdings in Zynex Inc.

Zynex, Inc. will hold its annual meeting on May 15, 2025, and has made proxy materials available online to conserve resources and reduce expenses.

Zynex, Inc. has scheduled its 2025 Annual Meeting of Stockholders for May 15, 2025, to address the election of directors and ratification of the independent public accountant.

Zynex, Inc. will hold its annual meeting on May 16, 2024, and has made proxy materials available online to conserve resources and reduce expenses.

Zynex, Inc. will hold its 2024 Annual Meeting of Stockholders on May 16, 2024, to elect directors and ratify the selection of its independent public accountant.